Key result
A low-intensity initiation of chemotherapy followed by a standard full-dose R-CHOP regimen achieved complete remission of primary cardiac lymphoma without cardiovascular complications.
Why the study?
Does a low intensity initiation of chemotherapy prevent cardiovascular complications in patients with primary cardiac lymphoma?
Case Report (n=1)
Does a low intensity initiation of chemotherapy prevent cardiovascular complications in patients with primary cardiac lymphoma?
A 'low and slow' initiation of chemotherapy with CICU monitoring may safely achieve remission in primary cardiac lymphoma while mitigating the risk of catastrophic cardiovascular complications from rapid tumor destruction.
Answers are grounded in this paper and cite their sources.
May support monitored low-intensity chemotherapy start in primary cardiac lymphoma; hypothesis-generating case report requiring prospective validation.
Primary cardiac lymphomas (PCL) are very rare lymphoid malignancies that originate in the heart or pericardium. Their clinical diagnosis is often difficult, as they infrequently present with signs and symptoms consistent with cardiopulmonary conditions. Typically when B symptoms develop, (fever, weight loss, fatigue common in lymphoid malignancies), progressive heart failure will ensue. Antineoplastic treatment of PCL carries the risk of rapid tumor destruction, causing significant cardiovascular complications including life threatening arrhythmias, pericardial effusion or ventricular septal rupture. While chemotherapy is recommended to treat PCL, prognosis and response to therapy are impacted by the cardiovascular complications. In this instance, a low intensity initiation of chemotherapy followed by the standard full-dose regimen was able to achieve complete remission without cardiovascular complications. Patient monitoring in the Cardiac Intensive Care Unit (CICU) while undergoing initial cycles of chemotherapy may further offer the opportunity to institute lifesaving treatment when encountering the aforementioned cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2014) conducted a case report in Primary cardiac lymphoma (n=1). Low and slow chemotherapy (rituximab, prednisone, R-CHOP) was evaluated on Complete remission and resolution of intracardiac lymphoma. A low-intensity initiation of chemotherapy followed by a standard full-dose R-CHOP regimen achieved complete remission of primary cardiac lymphoma without cardiovascular complications.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: